导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 0.70% | 2035/4773 |
| 近一周 | -2.04% | 1112/5462 |
| 近一月 | -3.79% | 1960/5421 |
| 近一季 | -6.58% | 2139/5209 |
| 近半年 | -1.68% | 1660/4920 |
| 近一年 | 3.55% | 1910/4366 |
| 近两年 | 55.11% | 1335/2954 |
| 近三年 | 35.31% | 853/2253 |
| 成立以来 | 87.47% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.97% 2977/4961 |
14.04% 1889/5312 |
- - |
- - |
| 2025 | 22.47% 1969/4813 |
-0.56% 2306/3635 |
2.07% 1900/4076 |
19.74% 2104/4524 |
0.77% 1780/4813 |
| 2024 | 17.20% 716/3463 |
2.72% 721/2808 |
-1.27% 1013/3014 |
16.85% 1332/3129 |
-1.11% 1592/3463 |
| 2023 | -9.47% 1168/2656 |
4.05% 1060/2280 |
-4.87% 1314/2385 |
-2.68% 719/2515 |
-6.02% 1597/2655 |
| 2022 | -19.20% 816/2207 |
-14.72% 988/1919 |
7.53% 458/2016 |
-13.04% 822/2113 |
1.32% 1307/2208 |
| 2021 | 4.41% 579/1822 |
-2.88% 719/1255 |
8.94% 598/1330 |
-3.29% 629/1466 |
2.05% 713/1822 |
| 2020 | 43.32% 249/1250 |
-6.92% 515/1028 |
17.00% 398/1067 |
16.00% 179/1164 |
13.45% 360/1184 |
| 2019 | 40.31% 257/1092 |
26.96% 367/754 |
-0.13% 225/804 |
2.65% 292/850 |
7.80% 396/918 |
| 2018 | - - |
- - |
- - |
- - |
-11.58% 321/691 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 南方MSCI中国A股国际通ETF VS. 长安沪深300非周期A(740101) |